LASIK for the Correction of High Hyperopic Astigmatism With Epithelial Thickness Monitoring by Reinstein, Dan Z et al.
  
LASIK for the correction of high hyperopic astigmatism with the Carl 1 
Zeiss Meditec MEL80 and CRS-Master and VHF Digital Ultrasound 2 
Epithelial Thickness Monitoring 3 
 4 
Dan Z Reinstein, MD MA(Cantab) FRCSC DABO FRCOphth FEBO1,2,3,4 5 
Glenn I Carp, MBBCh FC Ophth (SA)1 6 
Timothy J Archer, MA(Oxon) DipCompSci(Cantab)1,4 7 
Tim Buick, BSc MSc DipIPEM1 8 
Marine Gobbe, PhD MSTOptom1 9 
Elizabeth L Rowe, BSc (Hons)1 10 
Mario Jukic, BSc (Hons)1 11 
Emma Brandon, BSc (Hons) MCOptom MSc1 12 
Johnny Moore FRCOphth, PhD, MD4 13 
Tara Moore BSc, PhD4 14 
 15 
1. London Vision Clinic, London, UK 16 
2. Department of Ophthalmology, Columbia University Medical Center, NY, USA 17 
3. Centre Hospitalier National d’Ophtalmologie, Paris, France 18 
4. Biomedical Science Research Institute, University of Ulster, Coleraine, Northern Ireland 19 
 20 
Financial disclosure: Dr Reinstein is a consultant for Carl Zeiss Meditec (Carl Zeiss Meditec AG, Jena, 21 
Germany) and has a proprietary interest in the Artemis technology (ArcScan Inc, Morrison, Colorado) 22 
through patents administered by the Center for Technology Licensing at Cornell University (CTL), 23 
Ithaca, New York. The remaining authors have no proprietary or financial interest in the materials 24 
presented herein. 25 
  
 26 
Mr Timothy J Archer is joint first author, as part of his PhD with the University of Ulster. 27 
 28 
Correspondence: Dan Z Reinstein, MD MA(Cantab) FRCSC DABO FRCOphth FEBO, London Vision 29 
Clinic, 138 Harley Street, London W1G 7LA, United Kingdom. Tel +44 207 224 1005, Fax +44 207 224 30 
1055, email dzr@londonvisionclinic.com 31 
 32 
  33 
  
Abstract 34 
Purpose: To evaluate outcomes of high hyperopic LASIK using the MEL 80 excimer laser. 35 
Methods: Retrospective analysis of 785 consecutive high hyperopic LASIK procedures using the MEL 36 
80 excimer laser (Carl Zeiss Meditec) and either the VisuMax femtosecond laser (Carl Zeiss Meditec) 37 
or zero compression Hansatome (Bausch & Lomb) microkeratome. Inclusion criteria were attempted 38 
maximum hyperopic meridian ≥+4.00D and CDVA 20/20 or better. Patients were followed for a 39 
minimum of 1 year. Epithelial thickness monitoring by Artemis VHF digital ultrasound (ArcScan Inc) 40 
was used to evaluate potential for further steepening as a retreatment. A full review of the peer-41 
reviewed literature was carried out for comparative purposes. 42 
Results: Mean attempted SEQ was +4.52±0.84D (+2.00 to +6.96D) and mean cylinder was 43 
1.05±0.86D 44 
(0.00 to 5.25D). Mean age was 50±12 (18 to 70) with 61% female patients. Postoperative SEQ was 45 
±0.50 D in 50% and ±1.00 D in 77% of eyes, after primary treatment. After retreatment, 67% of eyes 46 
were ±0.50 D and 89% were within ±1.00 D. UDVA was 20/20 or better in 76% of eyes after final 47 
treatment. One line of CDVA was lost in 25% of eyes and two lines were lost in 0.4%. There was a 48 
clinically insignificant but statistically significant decrease (P<.05) in contrast sensitivity (CSV-1000) 49 
by less than 1 log unit at 3 and 6 cpd, and by 1 log unit at 12 and 18 CPD. Diurnal fluctuation in 50 
refraction was identified in 2 eyes, proven by VHF digital ultrasound to be due to diurnal epithelial 51 
remodelling overnight and unrelated to maximum postoperative keratometry induced. 52 
Conclusions: LASIK for hyperopia by cumulative treatment of up to +9.00 D with the MEL80 excimer 53 
laser was found to satisfy accepted criteria for safety, efficacy and stability. 54 
  55 
  
Introduction 56 
Excimer lasers have been used as a treatment for high hyperopia since Dausch et al1 first reported 57 
the results of PRK for hyperopia up to +7.50 D in 1993 using the MEL60 excimer laser (Carl Zeiss 58 
Meditec, Jena, Germany). Numerous reports followed with results of high hyperopia correction with 59 
first generation excimer lasers, but many of these were associated with significant regression,  60 
undercorrection, and loss of corrected distance visual acuity (CDVA)1-5 leading a number of clinicians 61 
to suggest that safe and effective excimer laser correction of hyperopia might be limited to 62 
treatments below +4.00 D or +5.00 D.2, 3 However, there are more recent reports of safe, effective 63 
and stable outcomes for hyperopia above +5.00 D using these first generation excimer lasers.6, 7  64 
 65 
The first major improvement in hyperopic corneal ablation surgery came relatively early on as 66 
different groups found improved results, in particular improved stability, by increasing the optical 67 
zone and transition zone size.3, 8, 9 The second major improvement was observed with the 68 
introduction of flying spot lasers to replace the broad beam scanning slit lasers, with an 69 
improvement in outcomes noted with the a variety of different lasers.7, 10-18 Thirdly, alongside the 70 
development of excimer laser technology, significant progress has been made with ablation profile 71 
design. Finally, results have been improved by changing the protocol for ablation centration from 72 
the entrance pupil center to the corneal vertex16, 19 or coaxially sighted corneal light reflex.18, 20, 21 73 
(Further references for the introduction are available in appendix A) 74 
 75 
The purpose of the present study was to report the refractive outcomes of LASIK with the MEL80 76 
excimer laser (Carl Zeiss Meditec, Jena, Germany) in a large number of eyes with high hyperopic 77 
refractive error of +4.00 D or more.  78 
  79 
  
Methods 80 
Patients 81 
This was a retrospective non-comparative consecutive case series including 835 eyes of 681 82 
hyperopic primary LASIK procedures between 14/05/2003 to 20/12/2011 at London Vision Clinic.  83 
 84 
Inclusion criteria were: attempted maximum hyperopic correction of ≥+4.00 D, medically suitable for 85 
LASIK, no previous ocular, eyelid or orbital surgery, no visually significant cataract, CDVA 20/20 or 86 
better, age ≤70 years old, and a minimum follow-up of 1 year. Informed consent and permission to 87 
use their data for general analysis and publication was obtained from each patient prior to surgery 88 
as part of our routine protocol. Because this was a retrospective study, institutional review board 89 
approval was not required. One patient did not provide permission, so was excluded from the 90 
analysis. 91 
 92 
A full ophthalmologic examination was performed by an in-house optometrist as described 93 
previously.11 This included a manifest refraction and a cycloplegic refraction according to a 94 
standardized protocol.22 The manifest refraction was repeated on a later date by the surgeon, which 95 
was used to plan the treatment. 96 
 97 
Planning 98 
In our protocol for high hyperopia, the following criteria must be met before the primary procedure. 99 
Firstly, the predicted post-operative residual stromal thickness must be greater than 250 µm. 100 
Secondly, the attempted correction was limited such that the predicted postoperative keratometry 101 
was less than 51.00 D. Finally, an arbitrary maximum laser data entry of +7.00 D was applied. 102 
Therefore, some patients were treated using a planned two-stage protocol where the primary 103 
procedure was an intentional undercorrection, followed by retreatment at a later date. 104 
 105 
  
Surgical Protocol 106 
All treatments were performed as bilateral simultaneous LASIK using the MEL80 excimer laser. The 107 
zero compression Hansatome microkeratome was used between 14/05/2003 and 10/07/2009 in 108 
38% of eyes and the VisuMax femtosecond laser was used between 05/10/2007 and 20/12/2011 in 109 
the other 62% of eyes. The procedure was performed by author DZR in 71% of eyes and by author 110 
GIC in 29% of eyes. The CRS-Master software platform was used to generate the ablation profiles. 111 
 112 
The standardized surgical technique followed has been described previously.23 Both the flap and 113 
corneal ablation were centered on the coaxially sighted corneal light reflex (CSCLR).20 During surgery, 114 
the CSCLR was determined before the flap was lifted as the first Purkinje reflex, seen as the patient 115 
fixated coaxially with the aiming beam and the view of the surgeon’s contralateral eye through the 116 
operating microscope. The CSCLR was used as the best approximation of the intersection of the 117 
visual axis with the cornea. 118 
 119 
Optical treatment zone diameters were 6.50-mm (in 18%) and 7.00-mm (in 82%). Intended flap 120 
thickness was 160 µm in 35% and 180 µm in 2% of eyes (using the Hansatome), and 90-95 µm in 121 
24%, 100 µm in 28%, 110 µm in 8%, and 120 µm in 2% of eyes (using the VisuMax). Flap diameter 122 
was 8.5 mm in 0.4% and 9.5 mm in 37% of eyes (using the Hansatome), and 8.0 mm in 16%, 8.5 mm 123 
in 0.5%, and 8.8 mm in 45% of eyes (using the VisuMax). For VisuMax flaps, a small contact glass was 124 
used for an 8.0-mm flap diameter, otherwise a medium contact glass was used. A 4.5-mm superior 125 
hinge was used in all VisuMax cases. 126 
 127 
Postoperative Course and Evaluation 128 
Patients were instructed to instill tobramycin with dexamethasone (Tobradex; Alcon Laboratories, 129 
Inc., Fort Worth, TX) and ofloxacin (Exocin; Allergan Ltd, Marlow, UK) four times daily and wear 130 
plastic shields for sleeping during the first week. The surgeon reviewed the patient at day 1 and flap 131 
  
adjustments were performed if necessary at the slit-lamp using a surgical spear under topical 132 
anesthetic and antibiotic cover. An in-house optometrist examined the patient at 1, 3, and 12 133 
months and yearly thereafter with surgeon review for all outliers. All visits included monocular and 134 
binocular UDVA, manifest refraction, and CDVA. Best spectacle-corrected mesopic contrast 135 
sensitivity, ATLAS corneal topography and dilated WASCA aberrometry (both Carl Zeiss Meditec) 136 
were performed at 3 months, 1 year, and 2 years. 137 
 138 
Postoperative complications and dry eye symptoms were assessed at each visit. A 6-grade 139 
classification system was used for each parameter: trace, GD I-II (not visually significant), and GD III-140 
V. In this scale, trace refers to any small amount inconsistent with an untreated cornea, even if not 141 
visually significant. 142 
 143 
Retreatments 144 
Retreatments followed the same protocol in those who had planned retreatments and in those who 145 
required retreatment following a full correction. Retreatments were performed once stability was 146 
demonstrated over an interval of at least two months, defined as no change in sphere within ±0.25 D 147 
and cylinder within ±0.25 D. 148 
 149 
In the majority of cases, an Artemis very high-frequency (VHF) digital ultrasound (ArcScan Inc, 150 
Morrison, Colo) scan was performed to obtain layered pachymetric maps of corneal, epithelial and 151 
residual stromal thickness.24 When planning a retreatment, the safety was assessed by checking that 152 
the predicted residual stromal thickness after the retreatment was greater than 250 µm at the 153 
location of the maximum ablation as well as the location of the (peripheral) minimum residual 154 
stromal thickness.  155 
 156 
  
Suitability was assessed using an epithelial thickness map to confirm that the minimum epithelium 157 
was sufficient to avoid apical syndrome if further steepening was induced. We have previously 158 
shown that the central epithelium thins by approximately 2 µm for every diopter of hyperopic 159 
correction using the MEL80.24 This can be used to predict the central minimum epithelial thickness 160 
after the retreatment and ensure that this remains greater than 28 µm. This is sufficient given that 161 
epithelial breakdown tends to occur for epithelial thicknesses of about 21 µm (personal 162 
communication, Dan Z. Reinstein). This method enables us to safely perform further steepening in 163 
cases that would otherwise have been excluded based on standard keratometry limits. According to 164 
these two safety factors, in some cases the retreatment performed was not a full correction. 165 
 166 
Statistical analysis 167 
Outcome analysis was performed according to the Standard Graphs for Reporting Refractive Surgery 168 
for both the primary treatment, and after the final treatment. Data from the 2-year visit were used 169 
for analysis if available, otherwise 1-year data were used. Stability of keratometry was evaluated as 170 
the mean simulated keratometry at 3 months, 1 year, and 2 years. The change in whole eye higher 171 
order aberrations was assessed using a 6-mm analysis zone. The incidence of postoperative 172 
complications and dry eye symptoms were assessed for the 1 year visit. Microsoft Excel 2010 173 
(Microsoft Corporation, Redmond, WA) was used for data entry and statistical analysis. A P value 174 
less than .05 was defined as statistically significant. 175 
  176 
  
Results 177 
Patient Population 178 
During the study period, 835 eyes were treated and a minimum of 1-year timepoint examination 179 
data were available for 790 eyes (95% follow-up), for which the last time point after the primary 180 
procedure was the 2 year visit in 57% (n = 448), the 1 year visit in 38% (n = 303), and the 6 month 181 
visit in 5% (n = 39) of eyes. All eyes where the last timepoint after the primary procedure was earlier 182 
than 1 year had undergone retreatment at that time. For these eyes, 1-year follow-up data after the 183 
retreatment were used to analyse the final outcome. Table 1 shows demographic data for the study 184 
population.  185 
 186 
Retreatments 187 
The primary procedure was performed as a partial correction in 20% (n = 158) of eyes, of which 51% 188 
(81/158) had undergone a retreatment to date. Of the 632 eyes intended for full correction, 35% 189 
(220/632) have undergone a retreatment. In total, including two stage protocol cases, 38% 190 
(301/790) of eyes have undergone a retreatment. Of these 301 eyes, a second retreatment was 191 
performed in 6 eyes (2%) within the two year follow-up period. Retreatments were performed at the 192 
6 month visit in 13% (n = 39), at the 1 year visit in 55% (n = 164), at the 2 year visit in 28% (n = 83), 193 
and after the 2 year visit in 4% (n = 12) of eyes. The mean attempted spherical equivalent of the 194 
retreatments was +1.08±0.96 D (-1.88 to +3.88 D), of which 6% (n = 18) were myopic, 82% (n = 243) 195 
were hyperopic, and 12% (n = 37) were mixed cylinder. 196 
 197 
Standard Outcomes 198 
Figure 1 presents the standard graphs for reporting refractive surgery after the primary treatment. 199 
Figure 2 presents the standard graphs for reporting refractive surgery after all treatments. Table 2 200 
shows the normalized mesopic contrast sensitivity data. There was a clinical insignificant but 201 
statistically significant decrease in contrast sensitivity (P < .001) representing less than half a patch at 202 
  
3 and 6 cpd, and almost one patch at 12 and 18 cpd. Table 3 summarizes the ocular aberrations 203 
preoperatively and after the primary treatment. Table 4 summarizes the change in keratometry over 204 
time.  205 
 206 
Complications 207 
In the 298 eyes treated using the zero compression Hansatome microkeratome, there were two flap 208 
complications. In the 492 eyes treated using the VisuMax femtosecond laser, there was 1 suction 209 
loss (0.2%), 1 peripheral buttonhole (0.2%), 1 peripheral cryptic buttonhole (0.2%), and 1 case of 210 
incomplete sidecut creation (0.2%). None of these complications resulted in abortion of the 211 
procedure or a loss of more than one line CDVA. Appendix B (available in the online version of the 212 
article) provides details of these complications. 213 
 214 
Table A (available in the online version of the article) provides the incidence of postoperative 215 
complications that required either a flap lift or Nd:Yag treatment (for epithelial ingrowth). There 216 
were also two cases of diurnal refractive fluctuations, with a myopic shift from morning to evening. 217 
These cases have been described in detail in a previous publication for an estimated overall 218 
incidence for this complication of 0.3%.25 Table B (available in the online version of the article) 219 
summarizes the incidence of postoperative complications as measured at the 1-year postoperative 220 
appointment. There were no visually significant complications (GD III-V). Table C (available in the 221 
online version of the article) summarizes the dry eye parameters both before and 1-year after 222 
surgery. All instances where a patient presented preoperatively with a form of dry eye of GD II or 223 
higher were actively managed prior to any surgery. 224 
  225 
  
Discussion 226 
The current study found the treatment of high hyperopia between +4.00 and +9.25 D using the MEL 227 
80 excimer laser to be safe and effective by using a two stage treatment protocol employing 228 
epithelial thickness mapping and monitoring. Although there was an increase in higher order 229 
aberrations, as expected for a high hyperopic correction, this increase was not visually harmful as 230 
demonstrated by only a very small decrease in contrast sensitivity, and only a 0.4% loss of 2 lines in 231 
CDVA. The two stage treatment protocol enabled a safer and more accurate final correction for high 232 
hyperopia in cases of undercorrection by regression but also enabling us to capitalise on cases that 233 
overcorrected after the primary procedure. These results show that LASIK is a safe and effective 234 
option for high hyperopia as an alternative to intraocular surgery, although the balance of risks and 235 
benefits must be carefully considered between these options. 236 
 237 
To compare the current study to published LASIK and intraocular lens studies, we performed a 238 
literature review for studies reporting results of hyperopia greater than +4.00 D. The main outcome 239 
parameters are shown in Table D for LASIK and Table E for intraocular lens procedures (tables and 240 
references available in online version of the article). Chronological examination of the LASIK studies 241 
shows a clear trend in improvement over time with modern excimer laser platforms showing a loss 242 
of 2 lines CDVA rate of between 0 and 6%. Further, some loss of CDVA would be expected as a 243 
matter of course due to the minification effect produced by corneal correction compared to 244 
spectacle correction. These rates are similar to the safety reported for refractive lens exchange 245 
where the loss of 2 or more lines ranged from 0 to 6.7%26 and in one study 11%.27 Such CDVA 246 
comparisons must also be considered in context of the more unusual but potentially catastrophic 247 
visual complications of intraocular surgery, which cannot be adequately assessed by studies with 248 
small populations. For example, refractive lens exchange has been associated with 249 
endophthalmitis,28 posterior capsule opacification,29 cystoid macular edema,30 retinal detachment,31 250 
and suprachoroidal haemorrhage.32 Equally, phakic intraocular lens implantation is associated with 251 
  
cataract formation,33 pupil ovalization,34 pigment dispersion,35 endothelial cell loss,36 and retinal 252 
complications.37 Long term safety of intraocular procedures should also be taken into account given 253 
that many of these patients are 50 or younger. Complications such as long term IOL dislocation,38 254 
capsular fibrosis, and posterior capsule opacification are often underreported. 255 
 256 
Postoperative dry eye exacerbation is another factor that should be considered when comparing 257 
corneal and intraocular interventions, given that LASIK involves disturbing the corneal nerve plexus. 258 
However, intraocular surgery also leads to exacerbation of meibomian gland dysfunction, dry eye 259 
and ocular discomfort albeit less so.39 In the present study, the only dry eye parameter that was 260 
greater at 1 year than before surgery was SPK. 261 
 262 
Corneal and intraocular approaches to treating high hyperopia are also differentiated in terms of 263 
possible achievable refractive correction, refractive stability over the medium and long term, and 264 
hence also refractive predictability. It is possible to achieve a larger degree of correction with 265 
intraocular surgery simply by changing the power of the lens, whereas hyperopic correction by LASIK 266 
has to abide by the limits of corneal steepening, epithelial thinning and potential regression. 267 
Therefore, the balance shifts toward intraocular surgery for very high hyperopia as reflected by the 268 
treatment range in the published studies compared to LASIK. However, some patients may opt for 269 
an undercorrection by LASIK as a compromise to completely avoid the more serious albeit unusual 270 
visually compromising complications of intraocular lens surgery. 271 
 272 
Intraocular lens procedures are inherently speaking more stable than corneal hyperopic procedures, 273 
but the refractive regression generally reported after hyperopic LASIK has been significantly reduced 274 
with the use of modern excimer laser systems and ablation profiles. In the present study, there is an 275 
initial over-correction which returned to target at 3 months, after which there was a hyperopic shift 276 
of about 0.10 D every 6 months. However, it is worth noting that hyperopic refractions progress with 277 
  
time regardless of whether refractive surgery has been performed; progression of 0.42 D across five 278 
years (0.08 D per year) has been reported in patients of 50 or older.40  279 
 280 
Refractive changes that may occur over many years after LASIK are often identified as a reason to 281 
opt for an intraocular procedure in high hyperopia given the perception that this would translate to 282 
better refractive predictability. However, a review of refractive predictability data between LASIK 283 
and IOL surgery shows that the percentage of eyes within ±0.50 D of the intended target was similar 284 
between modern LASIK and the intraocular procedures in the short to medium term. Whereas it 285 
might be expected for further hyperopic shift in the long term after LASIK, longer term studies on 286 
the stability of clear lens exchange surgery in younger non-cataract patients are lacking. 287 
 288 
In this series, two cases of a rare, idiosyncratic diurnal refractive fluctuation syndrome we have 289 
previously described were identified by VHF digital ultrasound layered anatomical imaging and 290 
shown to be due to epithelial remodelling from morning to evening following compression by the 291 
eyelid overnight.25 This phenomenon was found to also occur in eyes with hyperopia as low as +3.25 292 
D and in postoperative keratometry as low as 41.20 D, with a total incidence of 0.3%. In cases where 293 
persistent fluctuation remains, it may be necessary to reverse some of the steepening achieved in 294 
order to stabilise the corneal epithelial layer and hence address the root cause for the induced 295 
diurnal refractive fluctuations. 296 
 297 
Analysis of ocular higher order aberrations showed a significant increase in coma, spherical 298 
aberration and higher order RMS. However, the increase in coma can be largely attributed to the 299 
difference in where the treatment was centered and where the aberrations were measured, 300 
meaning that coma will be measured postoperatively when measured on the entrance pupil center. 301 
Spherical aberration induction on average was -0.52 µm, however this was offset by the spherical 302 
aberration being positive in the majority of eyes before surgery, meaning that the postoperative 303 
  
level of spherical aberration was not visually compromising. Induction of negative spherical 304 
aberration also carries the benefit of increasing the depth of field,11, 41, 42 something that can be 305 
taken advantage of if cataract surgery is required in the future enabling high quality monofocal 306 
lenses to be used in conjunction with micro-monovision rather than employing light transmission 307 
reducing multifocal IOLs. In the present study, there was a small decrease in contrast sensitivity, 308 
however this was no greater than the drop associated with multifocal intraocular lenses that are 309 
currently and commonly used world-wide for patients with this degree of high hyperopia. 310 
 311 
In summary, the treatment of high hyperopia within +4.00 to +7.50 D by LASIK with the MEL80 312 
employing epithelial thickness mapping and monitoring represents an equivalent and less-invasive 313 
alternative to an intraocular procedure in patients without visually significant cataract. 314 
Characterisation and comparison of long-term stability differences between LASIK and intraocular 315 
surgery needs further study in order to balance stability benefits against quality of life costs of the 316 
rare but more severe visual complications that may occur with intraocular procedures. 317 
  318 
  
Legends 319 
Figure 1: Nine standard graphs for reporting refractive surgery showing the visual and refractive 320 
outcomes for 792 high hyperopic eyes after initial treatment with the MEL 80 excimer laser and the 321 
VisuMax femtosecond laser (both Carl Zeiss Meditec) or the zero compression Hansatome 322 
microkeratome (Bausch & Lomb). UDVA = uncorrected distance visual acuity; CDVA= corrected 323 
distance visual acuity; D = diopters; Postop = postoperative; Preop = preoperative; SEQ = spherical 324 
equivalent refraction; TIA = target induced astigmatism; SIA = surgically induced astigmatism. 325 
 326 
Figure 2: Nine standard graphs for reporting refractive surgery showing the visual and refractive 327 
outcomes for 792 high hyperopic eyes after final treatment with the MEL 80 excimer laser and the 328 
VisuMax femtosecond laser (both Carl Zeiss Meditec) or the zero compression Hansatome 329 
microkeratome (Bausch & Lomb). UDVA = uncorrected distance visual acuity; CDVA= corrected 330 
distance visual acuity; D = diopters; Postop = postoperative; Preop = preoperative; SEQ = spherical 331 
equivalent refraction; TIA = target induced astigmatism; SIA = surgically induced astigmatism. 332 
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Table 1 – demographic and refractive data 
Number of eyes 785 
Number of patients 644 
Gender (% male / female) 39 / 61 
Age (years) 
50.4±12 
(18 to 70) 
Preoperative spherical equivalent refraction (D) 
+3.84±1.35 
(+0.63 to +8.38) 
Preoperative refractive astigmatism (D) 
1.05±0.86 
(0.00 to 5.25) 
Intended postoperative spherical equivalent 
refraction after primary treatment (D) 
-0.68±0.89 
(-1.88 to +2.75) 
Attempted spherical equivalent refraction 
correction in primary treatment (D) 
+4.52±0.84 
(+2.00 to +6.96) 
Attempted maximum hyperopic meridian 
correction in primary treatment (D) 
+5.04±0.84 
(+4.00 to +7.00) 
Spherical equivalent refraction relative to intended 
target after primary treatment (D) 
+0.30±0.85 
(-3.63 to +4.25) 
Refractive astigmatism after primary treatment (D) 
0.77±0.58 
(0.00 to 3.50) 
Intended postoperative spherical equivalent 
refraction after all treatments (D) 
-0.82±0.82 
(-2.38 to +2.50) 
Attempted spherical equivalent refraction 
correction including all treatments (D) 
+4.65±0.98 
(+2.00 to +8.33) 
Attempted maximum hyperopic meridian 
correction including all treatments (D) 
+5.18±0.99 
(+4.00 to +9.00) 
Spherical equivalent refraction relative to intended 
target after all treatments (D) 
+0.09±0.67 
(-2.38 to +2.50) 
Refractive astigmatism after all treatments (D) 
0.61±0.47 
(0.00 to 3.25) 
Pre-operative corneal thickness (µm) 
547±33 
(467 to 662) 
Scotopic pupil size (mm) 
5.10±0.96 
(2.05 to 7.85) 
Preoperative average keratometry (D) 
43.25±1.49 
(38.70 to 47.81) 
Average keratometry after primary treatment (D) 
46.64±1.90 
(40.99 to 51.85) 
Average keratometry after all treatments (D) 
46.80±1.99 
(41.50 to 54.50) 
 
  
  
Table 2 - Mean normalized mesopic contrast sensitivity ratio for before and after the primary 
treatment 
cpd Pre Post p-value 
3 0.97 0.95 ↓ <0.001 
6 0.94 0.90 ↓ <0.001 
12 0.92 0.85 ↓ <0.001 
18 0.83 0.72 ↓ <0.001 
 
cpd: cycles per degree, ↓: indicates a decrease in mesopic contrast sensitivity 
  
  
Table 3: Change in ocular aberrations  
 
 
  
 Pre Post Change t-test 
Coma (µm) 0.22±0.13 0.77±0.32 0.54±0.33 p<0.001 
Spherical Aberration (µm) 024±0.14 -0.28 ±0.21 -0.52±0.18 p<0.001 
High Order Root Mean 
Square  (µm) 
0.43±0.13 0.90±0.26 0.48±0.27 p<0.001 
  
Table 4: Change in mean simulated keratometry 
 
 
 
 
 
 
  
 n Mean K (D) P-value 
3 months 635 
46.9 ± 1.9 
41.3 to 52.4 
 
1 year 451 
46.6 ± 2.0 
41.0 to 51.8 
 
2 years 313 
46.6 ± 1.8 
41.0 to 51.5 
 
3-12 months change 371 
-0.34 ± 0.51 
-3.32 to 1.22 
<.01 
1-2 years change 211 
-0.13 ± 0.47 
-1.60 to 1.97 
<.01 
  
Table A: Incidence of postoperative complications requiring surgical intervention 
Postoperative complications after primary 
treatment requiring intervention (out of n = 785) 
Occurrence 
Percentage of 
Total 
Flap lift for trauma 3 0.38% 
Flap lift for inflammation 2 0.25% 
Postoperative complications after retreatment 
requiring intervention (out of n = 298) 
  
Flap lift for epithelial ingrowth 4 1.34% 
Nd:Yag for epithelial ingrowth 8 2.68% 
 
  
  
Table B – Incidence of postoperative complications at 1 year 
 Nil Trace 1 2 3 4 5 
Microfolds 99.9% 0.1% - - - - - 
Epithelial ingrowth 95.9% 3.1% 1.0% - - - - 
Interface haze 97.1% 2.9% - - - - - 
Infection 100% - - - - - - 
Interface debris 99.5% 0.5% - - - - - 
Diffuse lamellar keratitis 100% - - - - - - 
 
  
  
Table C – Incidence of dry eye parameter before and 1 year after surgery 
 Data indicated as percentages   Nil Trace 1 2 3 
SPK (exposure, inferior SPK) Pre 91.7 6.2 (1.0) 1.9 (0.6) 0.1 (0.0) 0.0 
SPK (exposure, inferior SPK) 1 year 72.4 18.0 (5.7) 7.5 (2.8) 2.2 (0.3) 0.0 
MGD Pre 67.5 22.2 8.0 2.2 0.1 
MGD 1 year 70.1 20.0 7.1 2.8 0.0 
Anterior blepharitis Pre 93.4 4.5 2.0 0.1 0.0 
Anterior blepharitis 1 year 96.4 2.4 1.1 0.0 0.0 
Posterior blepharitis Pre 95.3 2.4 2.0 0.1 0.1 
Posterior blepharitis 1 year 95.7 2.9 1.3 0.1 0.0 
Mixed blepharitis Pre 94.6 4.5 0.8 0.1 0.0 
Mixed blepharitis 1 year 98.1 1.5 0.4 0.0 0.0 
ABMD Pre 96.6 2.9 0.5 0.0 0.0 
ABMD 1 year 97.1 2.9 0.0 0.0 0.0 
Lash deposits Pre 99.9 0.1 0.0 0.0 0.0 
Lash deposits 1 year 99.7 0.1 0.0 0.0 0.1 
Meibomitis Pre 99.7 0.3 0.0 0.0 0.0 
Meibomitis 1 year 100.0 0.0 0.0 0.0 0.0 
Scurf Pre 99.7 0.3 0.0 0.0 0.0 
Scurf 1 year 99.6 0.4 0.0 0.0 0.0 
    Nil Present 
   Entropion Pre 99.9 0.1 
   Entropion  1 year 100.0 0.0 
   Ectropion Pre 99.9 0.1 
   Ectropion 1 year 99.9 0.1 
   Chalazion Pre 100.0 0.0 
   Chalazion 1 year 99.9 0.1 
   Pitted lid margins Pre 100.0 0.0 
   Pitted lid margins 1 year 99.9 0.1 
   Lid thickening Pre 100.0 0.0 
   Lid thickening 1 year 99.9 0.1 
   Blocked meibomian glands Pre 99.9 0.1 
   Blocked meibomian glands 1 year 99.9 0.1 
   Band keratopathy Pre 99.9 0.1 
   Band keratopathy 1 year 100.0 0.0 
    
  
Appendix A – Complete Introduction and References for Literature 1 
Review 2 
 3 
Introduction 4 
Excimer lasers have been used as a treatment for high hyperopia since Dausch et al1 first reported 5 
the results of PRK for hyperopia up to +7.50 D in 1993 using the MEL60 excimer laser (Carl Zeiss 6 
Meditec, Jena, Germany). Numerous reports followed with results of high hyperopia correction with 7 
first generation excimer lasers, but many of these were associated with significant regression,1-13 8 
undercorrection,14-16 and loss of corrected distance visual acuity (CDVA)1, 3, 6, 7, 9-11, 16, 17 leading a 9 
number of clinicians to suggest that safe and effective excimer laser correction of hyperopia might 10 
be limited to treatments below +4.00 D or +5.00 D.5-7, 12, 16, 18, 19 However, there are more recent 11 
reports of safe, effective and stable outcomes20 for hyperopia above +5.00 D using these first 12 
generation excimer lasers.8, 21-26 13 
 14 
The first major improvement in hyperopic corneal ablation surgery came relatively early on as 15 
different groups found improved results, in particular improved stability, by increasing the optical 16 
zone and transition zone size.7, 8, 21, 23, 27, 28 The second major improvement was observed with the 17 
introduction of flying spot lasers to replace the broad beam scanning slit lasers, with an 18 
improvement in outcomes noted with the MEL7029-31 and MEL8032, 33 (Carl Zeiss Meditec, Jena, 19 
Germany), the LADARVision26, 27, 34 (Alcon, Fort Worth, TX), the EC-500035 and NAVEX36 (NIDEK Co Ltd, 20 
Gamagori, Japan), the ESIRIS37-40 and Amaris41-46 (Schwind GmbH, Kleinostheim, Germany), and the 21 
Allegretto,47, 48  Eye-Q49 and EX50050 (Alcon, Fort Worth, TX). Thirdly, alongside the development of 22 
excimer laser technology, significant progress has been made with ablation profile design. Finally, 23 
results have been improved by changing the protocol for ablation centration from the entrance pupil 24 
center to the corneal vertex41-43, 51, 52 or coaxially sighted corneal light reflex.49, 53-56 25 
  
Literature Review 26 
A literature review was conducted to identify published LASIK3, 4, 6-8, 10-14, 16, 20, 22-27, 29, 31-39, 41-50, 57-59 27 
 (PRK studies were not included) and intraocular lens studies (clear lens exchange, phakic IOLs)60-76 28 
reporting results of hyperopic greater than +4.00 D. The main outcome parameters are shown in 29 
Table D for LASIK and Table E for intraocular lens procedures (references in the tables are according 30 
to the reference list included in this appendix, not the main article). 31 
  
       Accuracy UDVA Safety 
First Author Year N (eyes) Technique Preop SEQ Age (years) Timepoint 
Mean±SD 
(range) ±0.50D ±1.00D ≤20/20 ≤20/40 1 line 
≥2 
lines 
de Ortueta42 2016 38 
LASIK 
Amaris 
Carriazo-Pendular 
+4.07±0.90 
+2.38 to +5.75 
40±10 
18 to 57 6 months +0.28±0.58 61 96 18 84 8 8 
Arba Mosquera43 2016 46 
LASIK 
Amaris 
Carriazo-Pendular 
+3.64±1.42 
+1.27 to +6.18 
45±11 
18 to 62 6 months +0.39±0.43 61 93 30 85 13 6.5 
Plaza-Puche44 2016 51 
LASIK 
Intralase & Amaris  
OZ 6.2-6.9mm 
+6.33±0.83 
+5.00 to +8.50 
33±9 
21 to 54 6 months 
+0.50±1.06  
-0.50 to +3.38  71 53 98 11 6.5 
Amigo48 2015 
 
24 
 
Allegretto 400 Hz & 
Hansatome 
Wavefront Optimised 
+3.66±0.61 
+2.75 to +5.00 
39±9 
20 to 49 6 months 
+0.08± 0.56 
-0.75 to +1.25 57 96 67 92 21 4 
  16 
Aspheric Customised 
Profile 
OZ 6.5 mm 
+4.05±0.59 
+2.75 to +5.13   
+0.21±0.44 
-0.50 to +1.00 100 100 81 100 12 0.0 
Plaza-Puche45 2015 86 
LASIK 
Intralase & 
500kHz Amaris excimer 
OZ 6.3-7.0mm 
+2.66±1.68 
-1.38 to +5.75 
40±10 
23 to 64 36 months 
+0.40±0.65 
-1.63 to +2.00 70 85 76 99 6.2 1.2 
Antonios46 2015 53 LASIK Moria M2 & Amaris 
+2.25±1.06 
+0.75 to +5.00 
45±12 
19 to 61 6 months 
+0.22±0.75 
-1.25 to +1.75 43 72 85 92 0.0 0.0 
  72 LDV femto & Amaris +2.24±0.95 +0.50 to +4.75 
46±10 
18 to 66  
-0.32±0.76 
-2.13 to +1.50 65 90 88 100 0.0 0.0 
Alio41 2013 27 
LASIK 
Intralase & 
500kHz Amaris excimer 
OZ 6.2-6.9mm 
+6.33±0.83 
+5.00 to +8.50  6 months 
+0.55±1.09 
-0.50 to +3.38 70  44 92 8 0.0 
Kanellopoulos50 2012 34 LASIK Xtra IntraLase / FS200 
+3.40±1.78 
+0.25 to +8.00  2 years +0.20±0.40       
  34 LASIK Xtra EX500 
+3.15±1.46 
+0.25 to +8.00   -0.20±0.56       
Kanellopoulos49 2012 202 LASIK Eye-Q 
+3.04±1.75 
+0.75 to +7.25 
(sphere) 
40±12 
19 to 62 2 years 
-0.39±0.30 
(sphere) 76 94 59 96 2.9 2.4 
Kermani36 2009 52 
LASIK 
NAVEX 
OZ 6.5mm (TZ 9mm) 
(visual axis group) 
+2.57±1.26 
+0.13 to +5.63  3 months 
+0.29±0.70 
-1.00 to +1.75 81 96 51 95 21 10 
de Ortueta39 2009 33 
LASIK 
Carriazo-Pendular 
ESIRIS 
OZ 6.25mm 
+2.61±1.39 
+0.75 to +6.00 
52 
34 to 65 3 months 
+0.26±0.51 
-0.38 to +1.88 88 94    0.0 
Llovet32 2009 49 
LASIK 
Moria I 
MEL80 
OZ 6mm 
+3.30±1.30 
+3.60 to +6.25 
36.9 
20 to 56 1 year +0.40±0.60 63 90   8 4 
  
Reinstein33 2009 258 
LASIK 
Hansatome 
MEL80 
+2.54±1.16 
+0.25 to +5.75 
56 
44 to 66 1 year +0.09±0.48 79 95 86 100 17 0.0 
Young57 2009 
Sub-
group 
of 1659 
eyes 
LASIK 
IntraLase FS60 
S4 
+4.00 to +5.50  1 month    38   20 
Alio38 2008 51 LASIK ESIRIS 
+4.45±1.08 
+2.50 to +7.25  6 months 
+0.88±1.10 
-0.50 to +3.50 80 88 54 95 4 0.0 
Waring35 2008 279 
LASIK 
EC-5000 
OZ 6mm (TZ 9mm) 
+3.51±1.45 
+0.50 to +6.75 
50±9 
23 to 69 1 year 
+0.35±0.54 
-1.63 to +2.00 61 99 63 90 15 1.4 
Desai16 2008 12 
LASIK 
Hansatome 
Star S2 
OZ 5mm (TZ 9mm) 
+4.10±0.69 
+4.00 to +5.50 54±14 ≥3 years +0.59±1.18 32 68 17 67 0 9 
Alio58 2006 41 
LASIK 
Incl. retreatments 
Keracor 217C 
OZ 6mm 
5.30±0.90 
+4.00 to +7.75 31±11 1 year 
+0.30±1.30 
-2.50 to +3.50 46 63     
Alio37 2006 55 
LASIK 
Carriazo Pendular 
ESIRIS 
≥6mm 
+5.10±0.90 
+4.00 to +7.00  6 months 
+0.40±0.50 
0.00 to +2.00 86 91   5.5 1.8 
Spadea31 2006 100 
LASIK 
Hansatome 
MEL70 
OZ 6mm 
+4.49±1.20 
+2.25 to +7.25 
40±8 
22 to 55 2 years +0.29±0.66 70 92 64 96 6 0 
Kanellopoulos47 2006 23 
LASIK 
Moria M2 
Allegretto Wave 
+2.24±1.18 
+0.25 to +6.50  1 year 
+0.69±0.92 
0.00 to +1.50 71    8 0 
Jaycock13 2005 47 
LASIK 
Microkeratome (180um) 
Summit Apex Plus 
OZ 6.0mm 
+3.58±1.48 
+0.75 to +7.00 
51.5 
32 to 66 5 years +0.89±0.94 32 60 43 87 2.1 0 
Oral26 2004 39 LASIK S2 
+2.98±1.60 
+0.87 to +6.50 51±10 6 months +0.51±0.51 63 88 67 100 2.5 0.0 
  25 S3 +2.71±1.36 +1.00 to +5.37 58±9  +0.35±0.58 68 88 48 100 12 0.0 
  41 LADARVision +2.59±1.28 +0.62 to +5.62 53±10  +0.24±0.57 76 86 76 100 0.0 0.0 
Esquenazi12 2004 18 
LASIK 
ACS 
Keracor 117C 
OZ 5.5mm (8.5mm TZ) 
+5.48±1.23 
+4.25 to +7.25  5 years +2.24±1.00 22 33 10 42   
Zadok11 2003 26 
LASIK 
ACS 
Keracor 117CT 
OZ 5.0-8.5 
+4.29±0.89 
+3.00 to +5.90 
45 
19 to 65 1 year +0.21±0.60  92 23 92 11 0.0 
  22  +7.52±1.36 +6.00 to +10.00   +1.62±1.50  36 14 59 4 13 
  
El-Agha25 2003 40 S2 LASIK 
+2.86±1.28 
+1.38 to +6.50 
41±9 
35 to 63 9 months +0.44±0.57 
 
 86 68 100 22 0.0 
Carones27 2003 53 
LASIK 
SKBM 
LADARVision 
OZ 7mm 
+2.34±2.09 
+0.50 to +6.00 
40±10 
20 to 58  
-0.22±0.41 
-1.75 to +0.75 79 98 53 100 4 0.0 
Lian24 2002 54 
LASIK 
ACS 
Keracor 117C 
PZ 5-5.5 (TZ 8.5-9.5) 
+3.12 
+1.00 to +5.75 
38±13 
18 to 55 1 year +0.29±0.78 61 83 63 93 12 1.9 
Ditzen29 2002 23 
LASIK 
Hansatome 
MEL70 
Spherical 
+4.88±2.13 
+2.13 to +9.63 
28 
20 to 42 1 year 
+0.30±0.90 
-0.75 to +2.50 78  39 83 6 0.0 
  44 Astigmatic +4.33±2.15 +0.50 to +9.50 
30 
25 to 43  
+0.29±1.27 
-3.25 to +3.25 42  4 63 4 4 
Cobo-Soriano10 2002 74 
LASIK 
Moria LSK-One 
Keracor 217CT 
+4.40±0.30 
+4.00 to +4.90 
35.5 
18 to 65 8 months   82 - - - 2.8 
  56  +5.30±0.20 +5.00 to +5.90     80    5.8 
  47  +6.50±0.50 +6.00 to +7.90     80    16.6 
Salz34 2002 39 
LASIK 
Hansatome 
LADARVision 
OZ 6mm (TA 9mm) 
Spherical 
+3.00 to +6.00  6 months  41 69 29 79  2.6 
  48 Astigmatic +3.00 to +5.75    46 79 32 84  8.5 
Choi20 2001 32 
LASIK 
Hansatome 
S2 
+4.00±4.50 
+1.50 to +8.75 
55 
35 to 71 6 months 
+0.30±1.70 
-3.00 to +2.70 34 53  66 25 9 
Tabbara14 2001 80 
LASIK 
ACS 
Keracor 117C 
+3.40±2.00 
+0.50 to +11.50 
42±13 
18 to 65 6 months 
+0.26±0.80 
-2.00 to +3.50 58 84 44 98  1.25 
Argento8 2000 251 
LASIK 
Microkeratome (160um) 
Keracor 117CT 
4.5-5.5mm OZ 
+5.28±0.69 
+5.50 to +8.50 
30.9% <40 
69.1% >40 1 year +0.88±0.96 52 81  78 5 0.0 
  32 5.9mm OZ +5.13±0.61 +5.00 to +8.50 
19.1% <40 
80.9% >40  -0.48±0.45 52 93  77 5 0.0 
Esquenazi7 1999 58 
LASIK 
Chiron 
Keracor 117CT 
OZ 5-7mm 
+4.50±1.73 
+1.75 to +8.50 
47 
20 to 63 1 year 
+0.88±1.87 
-1.25 to +2.50 61 73 35 81 6 6 
Barraquer23 1999 30 
LASIK 
Chiron 
Schwind-Keratom II 
OZ 7mm 
+4.67 
+3.51 to +6.00  6 months 
+0.82 
0.00 to +2.50  80    0.0 
  18  +7.44 +6.01 to +10.00   
+1.10 
-0.50 to +3.00  77    0.0 
  
Arbelaez6 1999 20 
LASIK 
ACS 
Keracor 117C 
4.5-5.5mm (TZ 8mm) 
+3.10 to +5.00  1 year  43 83 28 93 24 0.0 
  16  +5.10 to +9.00    38 50 0 50 24 12 
  14  +3.10 to +5.00    41 58 10 81 21 7 
  13  +5.10 to +9.00    17 17 0 15 61 15 
Argento4 1998 95 
LASIK 
Chiron 
Keracor 117CT 
5.0-5.5mm OZ 
+5.28±0.69  6 months +0.88±0.96 10 71 45  6 0.0 
Goker22 1998 54 
LASIK 
ACS 
Keracor 116 
OZ 8.5mm 
+6.50±1.33 
+4.25 to +8.00 
24 
21 to 64 18 months +0.44±1.95 39 76 15 67  6.8 
Ditzen3 1998 23 
LASIK 
ACS 
MEL60 
OZ 5mm 
+5.28±1.92 
+4.25 to +8.00 33±12 1 year 
+1.91 
-0.08 to +3.71    13 4.3 7.3 
 32 
  33 
  
       Accuracy UDVA Safety 
First Author Year N (eyes) Technique Preop SEQ Age (years) Timepoint 
Mean±SD 
(range) ±0.50D ±1.00D ≤20/20 ≤20/40 1 line 
≥2 
lines 
Hua60 2013 19 CLE + piggyback IOL +9.81±2.62 +6.00 to +14.50 
45±8 
32 to 55 2 years -0.20±1.39 31.6 68.4  21 21 11 
Ferrer-Blasco61 2012 30 CLE (ReSTOR) +4.52±1.14 +3.00 to +7.00 
52 
44 to 60 6 months -0.04±0.46 33 97   0.0 6.67 
Alfonso62 2011 45 CLE (AcriLISA) +3.53±2.29 +0.25 to +10.00 
55 
45 to 64 6 months 
-0.15±0.40 
-0.50 to +1.25 87 93   24 0.0 
Alfonso63 2009 41 LASIK + CLE (ReSTOR) +2.71±1.61 +1.25 to +5.50 
51±6 
45 to 65 6 months 
-0.06±0.51 
-1.25 to +1.25 73    22 2.4 
Fernandez-
Vega64 2007 158 CLE (ReSTOR) 
+3.86±2.52 
+0.75 to +8.50 
53±6 
45 to 70 6 months +0.23±0.32 89 100   11 0.0 
Pop65 2004 19 CLE (Acrysof / PMMA) +2.75 to +7.50 26 to 46 2 month +0.18±0.71 55 91  82 0.0 0.0 
Preetha66 2003 20 CLE (Staar IOL / Rayner) +6.66±2.17 +4.75 to +13.00 
36 
19 to 50 16 months 
+0.68±0.67 
0.00 to +2.50 70 90 10 50 10 0.0 
Dick67 2002 26 CLE (Array IOL) +3.04±1.04 +1.63 to +5.75 
52 
44 to 62 6 months 
+0.04±0.45 
-0.83 to +1.00 88 100 31 100 0.0 0.0 
Fink68 2000 24 CLE (SurgiAA-4203V) +6.32±1.32 +4.75 to +10.25 54.7 10 months 
+1.02±0.16 
+0.67 to +1.25 71 88 25 63 29 0.0 
Siganos69 1998 35 CLE (Coburn) +9.19±0.34 +6.75 to +13.75 
40 
19 to 55 5 years 
+0.02±0.82 
-2.50 to +3.00 74 91 14 100 0.0 0.0 
Lyle70 1997 20 CLE (Chiron / Ioptex) +4.73±1.98 +2.38 to +7.63 
49±6 
37 to 60 2 years 
-0.21±0.95 
-2.25 to +1.88  75  85 15 0.0 
Guell71 2008 41 Artisan +4.92±1.70 32 4 years -0.11±0.74 35 64 0 43   
Munoz72 2005 39 Artisan + LASIK +7.39±1.30 +5.25 to +9.75 
26 
23 to 31 1 year 
+0.06±0.52 
-1.50 to +0.75 80 95 17 90 23 0.0 
Pop65 2004 19 Artisan +2.75 to +9.25 20 to 41 2 month -0.03±0.75 50 78  89 0.0 0.0 
Saxena73 2003 26 Artisan +6.80±1.97 +3.00 to +11.00 
44 
28 to 60 6 months 
-0.08±0.74 
-1.50 to +1.38 59 86 50 96 11 0.0 
Alio74 2002 29 Artisan +6.06±1.26 +3.00 to +9.00 
34 
19 to 54 1 year 
0.10±0.57 
-1.00 to +2.00 79 97 7 66 3.4 0.0 
Pesando75 1999 15 ICL +7.77±2.08 +4.75 to +11.75 
38 
22 to 56 1 year 
+0.02±0.64 
1.00 to +1.50 69 92 0 46 8 0.0 
Davidorf76 1998 24 ICL +6.51±2.08 +3.75 to +10.50  8 months 
-0.39±1.29 
+1.25 to -3.88 58 79 8 63  4 
 34 
 35 
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Appendix B – Intraoperative and postoperative complications 
 
Intraoperative complications for Hansatome treated eyes 
The first case was of an irregular bed in one eye of the patient, where a shallow linear step in the 
bed was noted, but ablation was carried out as planned with no subsequent impact on the final 
refractive or visual outcome. In the second case, there was a very small (0.25 mm) “button” on the 
stromal surface with no associated defect in the flap overlying this – a cryptic buttonhole. The 
epithelium was manually removed from the “button” to reveal the shiny aspect of Bowman’s layer 
prior to the ablation, after which the flap was replaced with excellent edge apposition. The patient 
was prescribed fluorometholone 0.1% eye drops (FML; Allergan, Irvine, CA) for four weeks, however 
this eye developed trace interface haze associated with a -1.50 D overcorrection in outcome (this 
was the outlier overcorrection in the population). A PRK retreatment with mitomycin-C 0.02% for 60 
seconds was performed 6 months after the primary surgery. Postoperatively, there was no 
indication of interface haze after this retreatment and the final CDVA was 20/25, one line less than 
preoperatively. 
 
Intraoperative complications for VisuMax treated eyes 
In one eye, there was incomplete protection of the hinge, which meant that part of the peripheral 
hyperopic ablation profile was inadvertently applied to the edge of the hinge resulting in ablation 
through the stromal component of the flap in this area. This was recognised when checking the flap 
at the slit-lamp immediately after surgery and managed conservatively with a bandage contact lens 
until the epithelial defect had healed without consequences. At 5 months after surgery, this eye 
recovered the preoperative CDVA of 20/16. 
 
In the case of the cryptic buttonhole, the surface of Bowman’s layer was exposed by scraping the 
epithelium prior to the ablation. A bandage contact lens was applied and the final result was a loss 
  
of 1 line CDVA at 2 years. In the case of suction loss, this occurred after about 20% of the interface 
had been ablated, in the periphery due to the out to in scan direction. The contact glass was 
reapplied and the flap was created successfully using the same flap settings. Minimal flap slivers 
were noted in the temporal periphery, which were carefully positioned and the flap was replaced. 
There was a loss of 1 line CDVA in this eye at 2 years. There was incomplete femtosecond sidecut 
creation in one eye in the inferior region, which was manually dissected by a rhexis fashion following 
which the flap was lifted and replaced as normal. There was a loss of 1 line CDVA in this at 2 years, 
although trace ABMD was noted. 
 
 
 


